Inovio Pharmaceuticals Inc INO.OQ INO.O is expected to show a fall in quarterly revenue when it reports results on November 14 for the period ending September 30 2024
The San Diego California-based company is expected to report a 73.1% decrease in revenue to $104.5 thousand from $388 thousand a year ago, according to the mean estimate from 6 analysts, based on LSEG data.
LSEG's mean analyst estimate for Inovio Pharmaceuticals Inc is for a loss of $1.15 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Inovio Pharmaceuticals Inc is 13.50, above its last closing price of $5.15.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -1.12 | -1.10 | -1.19 | Missed | -8 |
Jan. 1 2024 | -1.01 | -1.00 | -1.31 | Missed | -30.6 |
Dec. 31 2023 | -1.42 | -1.27 | -1.12 | Beat | 11.6 |
Sep. 30 2023 | -1.50 | -1.52 | -1.56 | Missed | -2.6 |
Jun. 30 2023 | -1.81 | -1.74 | -1.56 | Beat | 10.3 |
Jan. 1 0001 | -1.76 | -1.74 | -1.92 | Missed | -10.3 |
Dec. 31 2022 | -2.01 | -2.02 | -2.52 | Missed | -25 |
Sep. 30 2022 | -3.56 | -3.55 | -1.80 | Beat | 49.3 |
This summary was machine generated November 13 at 00:02 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。